Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.93
(2.24%)
USD 0.93
(2.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 623.38 Million USD | 359.43% |
| 2022 | -240.28 Million USD | -66.49% |
| 2021 | -144.32 Million USD | -258.36% |
| 2020 | 91.13 Million USD | -64.15% |
| 2019 | 254.19 Million USD | 5.59% |
| 2018 | 240.75 Million USD | -12.27% |
| 2017 | 274.43 Million USD | -13.92% |
| 2016 | 318.79 Million USD | 165.23% |
| 2015 | 120.19 Million USD | 16.67% |
| 2014 | 103.02 Million USD | -0.42% |
| 2013 | 103.45 Million USD | 176.0% |
| 2012 | -136.13 Million USD | -57.15% |
| 2011 | -86.62 Million USD | -98.09% |
| 2010 | -43.73 Million USD | 63.5% |
| 2009 | -119.81 Million USD | -82.64% |
| 2008 | -65.6 Million USD | -10.32% |
| 2007 | -59.46 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 568.88 Million USD | -8.74% |
| 2024 Q2 | 534.73 Million USD | -6.0% |
| 2023 Q4 | 623.38 Million USD | -1.13% |
| 2023 Q3 | 630.48 Million USD | -1.55% |
| 2023 Q2 | 640.42 Million USD | 297.36% |
| 2023 Q1 | -324.5 Million USD | -35.05% |
| 2023 FY | 623.38 Million USD | 359.43% |
| 2022 Q3 | -158.2 Million USD | -79.2% |
| 2022 Q4 | -240.28 Million USD | -51.89% |
| 2022 FY | -240.28 Million USD | -66.49% |
| 2022 Q1 | -56.6 Million USD | 60.78% |
| 2022 Q2 | -88.28 Million USD | -55.95% |
| 2021 Q3 | -104.14 Million USD | -270.14% |
| 2021 Q1 | 20.61 Million USD | -77.38% |
| 2021 FY | -144.32 Million USD | -258.36% |
| 2021 Q2 | -28.13 Million USD | -236.49% |
| 2021 Q4 | -144.32 Million USD | -38.58% |
| 2020 Q4 | 91.13 Million USD | -35.3% |
| 2020 FY | 91.13 Million USD | -64.15% |
| 2020 Q1 | 205.78 Million USD | -19.04% |
| 2020 Q2 | 189.49 Million USD | -7.92% |
| 2020 Q3 | 140.86 Million USD | -25.66% |
| 2019 FY | 254.19 Million USD | 5.59% |
| 2019 Q2 | 333.2 Million USD | -12.09% |
| 2019 Q3 | 296.03 Million USD | -11.15% |
| 2019 Q4 | 254.19 Million USD | -14.13% |
| 2019 Q1 | 379.03 Million USD | 57.44% |
| 2018 Q4 | 240.75 Million USD | -10.08% |
| 2018 FY | 240.75 Million USD | -12.27% |
| 2018 Q3 | 267.74 Million USD | 2.3% |
| 2018 Q2 | 261.73 Million USD | 1.09% |
| 2018 Q1 | 258.9 Million USD | -5.66% |
| 2017 Q2 | 210.82 Million USD | -17.68% |
| 2017 FY | 274.43 Million USD | -13.92% |
| 2017 Q3 | 233.7 Million USD | 10.85% |
| 2017 Q4 | 274.43 Million USD | 17.43% |
| 2017 Q1 | 256.09 Million USD | -19.67% |
| 2016 FY | 318.79 Million USD | 165.23% |
| 2016 Q3 | 191.79 Million USD | 92.2% |
| 2016 Q4 | 318.79 Million USD | 66.22% |
| 2016 Q1 | 98.59 Million USD | -17.97% |
| 2016 Q2 | 99.78 Million USD | 1.21% |
| 2015 Q3 | 134.62 Million USD | 6.53% |
| 2015 Q4 | 120.19 Million USD | -10.72% |
| 2015 Q1 | 111.11 Million USD | 7.86% |
| 2015 FY | 120.19 Million USD | 16.67% |
| 2015 Q2 | 126.36 Million USD | 13.72% |
| 2014 Q4 | 103.02 Million USD | -19.18% |
| 2014 Q1 | -26.43 Million USD | -125.56% |
| 2014 Q2 | 83.62 Million USD | 416.29% |
| 2014 Q3 | 127.46 Million USD | 52.43% |
| 2014 FY | 103.02 Million USD | -0.42% |
| 2013 Q1 | 69.79 Million USD | 151.27% |
| 2013 Q4 | 103.45 Million USD | 197.8% |
| 2013 Q3 | 34.74 Million USD | 178.22% |
| 2013 Q2 | -44.41 Million USD | -163.63% |
| 2013 FY | 103.45 Million USD | 176.0% |
| 2012 Q2 | -86.44 Million USD | 33.97% |
| 2012 Q1 | -130.9 Million USD | -51.11% |
| 2012 Q4 | -136.13 Million USD | -8.71% |
| 2012 Q3 | -125.22 Million USD | -44.87% |
| 2012 FY | -136.13 Million USD | -57.15% |
| 2011 Q4 | -86.62 Million USD | -27.19% |
| 2011 Q2 | -47.41 Million USD | -4.5% |
| 2011 Q1 | -45.37 Million USD | -3.76% |
| 2011 FY | -86.62 Million USD | -98.09% |
| 2011 Q3 | -68.11 Million USD | -43.65% |
| 2010 FY | -43.73 Million USD | 63.5% |
| 2010 Q4 | -43.73 Million USD | 24.7% |
| 2010 Q3 | -58.07 Million USD | -79.2% |
| 2010 Q2 | -32.4 Million USD | 55.75% |
| 2010 Q1 | -73.22 Million USD | 38.88% |
| 2009 Q4 | -119.81 Million USD | -29.33% |
| 2009 Q3 | -92.64 Million USD | 0.0% |
| 2009 FY | -119.81 Million USD | -82.64% |
| 2008 Q4 | -65.6 Million USD | 0.0% |
| 2008 FY | -65.6 Million USD | -10.32% |
| 2007 FY | -59.46 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -561.717% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -731.733% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | -43.196% |
| Cosmos Health Inc. | 8.59 Million USD | -7156.45% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 7689.77% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -35.903% |
| Cronos Group Inc. | -663.32 Million USD | 193.978% |
| Incannex Healthcare Limited | -5.48 Million USD | 11465.251% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 4377.958% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -411.398% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 21585.42% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 4087.197% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 4087.197% |
| SCYNEXIS, Inc. | -19.35 Million USD | 3321.623% |
| Safety Shot Inc | -2.28 Million USD | 27389.04% |
| Theratechnologies Inc. | 24.87 Million USD | -2406.469% |
| Alpha Teknova, Inc. | 1.97 Million USD | -31479.737% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -316003.22% |
| Pacira BioSciences, Inc. | 432.74 Million USD | -44.053% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 24837.46% |
| Dynavax Technologies Corporation | 106.63 Million USD | -484.596% |
| Radius Health, Inc. | 359.28 Million USD | -73.509% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 6710.835% |
| Alvotech | 1.06 Billion USD | 41.429% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 576.488% |
| SIGA Technologies, Inc. | -148.68 Million USD | 519.274% |
| Shineco, Inc. | 29.29 Million USD | -2028.295% |
| Silver Spike Investment Corp. | -32.61 Million USD | 2011.539% |
| Journey Medical Corporation | -9.7 Million USD | 6520.682% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 12418.907% |
| Embecta Corp. | 1.31 Billion USD | 52.486% |
| Harrow Health, Inc. | 116.41 Million USD | -435.475% |
| Procaps Group, S.A. | 242.93 Million USD | -156.608% |
| Biofrontera Inc. | 4.05 Million USD | -15269.428% |
| DURECT Corporation | -7.65 Million USD | 8244.552% |
| PainReform Ltd. | -7.95 Million USD | 7941.308% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1959.349% |
| OptiNose, Inc. | 58.06 Million USD | -973.597% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 12120.445% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -4052.295% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -583270.61% |
| ProPhase Labs, Inc. | 19.23 Million USD | -3141.558% |
| Phibro Animal Health Corporation | 454.84 Million USD | -37.054% |
| Procaps Group S.A. | 242.93 Million USD | -156.608% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -16848.994% |
| Viatris Inc. | 17.13 Billion USD | 96.361% |
| Rockwell Medical, Inc. | 4.45 Million USD | -13889.767% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 12882.12% |
| Tilray Brands, Inc. | 158.97 Million USD | -292.122% |
| PetIQ, Inc. | 351.93 Million USD | -77.131% |
| Talphera, Inc. | -5.72 Million USD | 10996.417% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -251.598% |
| Alimera Sciences, Inc. | 55.3 Million USD | -1027.093% |
| Assertio Holdings, Inc. | -32.52 Million USD | 2016.395% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 41973.768% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -14682.642% |
| Hempacco Co., Inc. | 13.61 Million USD | -4478.764% |
| Alvotech | 1.06 Billion USD | 41.429% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 744.591% |
| Kamada Ltd. | -46.43 Million USD | 1442.588% |
| Currenc Group, Inc. | -16.57 Million USD | 3861.415% |
| Indivior PLC | -33.95 Million USD | 1936.075% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -239134.92% |
| Flora Growth Corp. | -713 Thousand USD | 87531.136% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 7689.77% |
| Evolus, Inc. | 63.7 Million USD | -878.502% |
| HUTCHMED (China) Limited | -197.45 Million USD | 415.705% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | -30.113% |
| Akanda Corp. | 3.9 Million USD | -15864.082% |